Abstract
After a short historical review of the development of the pharmaceutical treatment of the epilepsies the author reviews some of the possible strategies to manage patients with the different types of epilepsies and epileptic syndromes using the classical drugs. A strategy used by most of the physicians uses Sodium Valproate as the first line drug for almost all patients. This may be replaced by other drugs according to their efficacy against the different types of seizures to be treated whenever VPA has not enough efficacy or isnt well tolerated. On the other hand epileptologists use the different drugs according to the different epilepsies and epileptic syndromes depending on the relative efficacy of each drug available and the possible side effects. He then describes succinctly the better-known new drugs and makes some comments on the coming drugs now in development. Finally he proceeds to include them in the strategies above described. Lamotrigine and possibly Topiramate are good candidates to replace VPA in the one drug strategy. Lamotrigine, Oxcarbamazepine and possibly Gabapentin may be used in the future as 1 st line drugs in selected patients. Vigabatrin is already used as one of the better alternatives for West syndrome and Oxcarbamazepine has replaced Carbamazepine in countries where its available to the public. Some drawbacks have been apparent with these drugs like the hepatic and haematological toxic effect of Felbamate or the apparently irreversible fields constriction provoked by Vigabatrin, which did limit their use.
Keywords: Epilepsy, Benzodiazepines, Etosuximide, Sodium Valproate, Carbamazepine, phenytoin, Vigabatrin, GABA transaminase, Oxcarbazepine, OXC, Lamotrigine, Gabapentin, Topiramate, Zonisamide
Current Pharmaceutical Design
Title: The New Drugs and the Strategies to Manage Epilepsy
Volume: 6 Issue: 8
Author(s): Jose M. Lopes Lima
Affiliation:
Keywords: Epilepsy, Benzodiazepines, Etosuximide, Sodium Valproate, Carbamazepine, phenytoin, Vigabatrin, GABA transaminase, Oxcarbazepine, OXC, Lamotrigine, Gabapentin, Topiramate, Zonisamide
Abstract: After a short historical review of the development of the pharmaceutical treatment of the epilepsies the author reviews some of the possible strategies to manage patients with the different types of epilepsies and epileptic syndromes using the classical drugs. A strategy used by most of the physicians uses Sodium Valproate as the first line drug for almost all patients. This may be replaced by other drugs according to their efficacy against the different types of seizures to be treated whenever VPA has not enough efficacy or isnt well tolerated. On the other hand epileptologists use the different drugs according to the different epilepsies and epileptic syndromes depending on the relative efficacy of each drug available and the possible side effects. He then describes succinctly the better-known new drugs and makes some comments on the coming drugs now in development. Finally he proceeds to include them in the strategies above described. Lamotrigine and possibly Topiramate are good candidates to replace VPA in the one drug strategy. Lamotrigine, Oxcarbamazepine and possibly Gabapentin may be used in the future as 1 st line drugs in selected patients. Vigabatrin is already used as one of the better alternatives for West syndrome and Oxcarbamazepine has replaced Carbamazepine in countries where its available to the public. Some drawbacks have been apparent with these drugs like the hepatic and haematological toxic effect of Felbamate or the apparently irreversible fields constriction provoked by Vigabatrin, which did limit their use.
Export Options
About this article
Cite this article as:
Lopes Lima M. Jose, The New Drugs and the Strategies to Manage Epilepsy, Current Pharmaceutical Design 2000; 6 (8) . https://dx.doi.org/10.2174/1381612003400308
DOI https://dx.doi.org/10.2174/1381612003400308 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employed in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, and prediction, to monitoring of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Gabapentin-Mediated Effects on Voltage- and Ligand-Gated Currents
Current Neuropharmacology Pregabalin Treatment does not Affect Amyloid Pathology in 5XFAD Mice
Current Alzheimer Research Gliomas: Current Issues in Diagnosis and Treatment
Current Medical Imaging Metabotropic Glutamate Receptor 7 (mGluR7) as a Target for the Treatment of Psychostimulant Dependence
CNS & Neurological Disorders - Drug Targets Purine Ionotropic (P2X) Receptors
Current Pharmaceutical Design Synthesis and Evaluation of Phenyliminoindolin-Containing Phenylacetamide Derivatives with the Antidepressant and Anticonvulsant Effects
Medicinal Chemistry Stress Level of Parents of Children Diagnosed with Attention-deficit/ Hyperactivity Disorder (ADHD) in Dubai, United Arab Emirates
New Emirates Medical Journal Diagnostic Biomarkers of Epilepsy
Current Pharmaceutical Biotechnology High-Level Expression and Purification of an Analgesic Peptide from Buthus martensii Karch
Protein & Peptide Letters Febrile Infection-Related Epilepsy Syndrome (FIRES): An Overview of Treatment and Recent Patents
Recent Patents on Inflammation & Allergy Drug Discovery Preface
Current Drug Targets - CNS & Neurological Disorders Old and New Antiepileptic Drugs for the Treatment of Idiopathic Generalized Epilepsies
Current Clinical Pharmacology Diagnostic Boundaries of Autism Disorder Vs Pervasive Developmental Disorder Nos Comparative Observational Study and Literature Review
Current Clinical Pharmacology MicroRNAs: Key Players in Microglia and Astrocyte Mediated Inflammation in CNS Pathologies
Current Medicinal Chemistry Association and Causal Relationship of Midlife Obesity and Related Metabolic Disorders with Old Age Cognition
Current Alzheimer Research Warfarin Dosing and the Promise of Pharmacogenomics
Current Clinical Pharmacology A Case of Topiramate-Induced Epistaxis
Current Drug Safety Vascular and Parenchymal Mechanisms in Multiple Drug Resistance: a Lesson from Human Epilepsy
Current Drug Targets An Insight into the Role of Artificial Intelligence in the Early Diagnosis of Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets The Importance of Citicoline in Combined Treatment in Dementia: What did the Citimem Study Teach us?
Reviews on Recent Clinical Trials